Literature DB >> 22465738

A revolution in HCV treatment with direct-acting antivirals: from non-response to eradication.

Tarik Asselah1.   

Abstract

Year:  2012        PMID： 22465738     DOI： 10.1016/j.jhep.2012.03.005

Source DB:  PubMed          Journal:  J Hepatol        ISSN： 0168-8278            Impact factor:   25.083


× No keyword cloud information.
  5 in total

1.  Interleukin 28A.rs12980602 and interleukin 28B.rs8103142 genotypes could be protective against HCV infection among Egyptians.

Authors:  Zainab A Zakaria; Susanne Knapp; Mohamed Hashem; Hassan Zaghla; Mark Thursz; Imam Waked; Sayed Abdelwahab
Journal:  Immunol Res       Date:  2019-02       Impact factor: 2.829

2.  KIR2DL2/C1 is a Risk Factor for Chronic Infection and Associated with Non-response to PEG-IFN and RBV Combination Therapy in Hepatitis C Virus Genotype 1b Patients in China.

Authors:  Song Hu; Fahu Yuan; Lingyan Feng; Fang Zheng; Feili Gong; Hanju Huang; Binlian Sun
Journal:  Virol Sin       Date:  2018-07-23       Impact factor: 4.327

3.  Progressive loss of memory T cell potential and commitment to exhaustion during chronic viral infection.

Authors:  Jill M Angelosanto; Shawn D Blackburn; Alison Crawford; E John Wherry
Journal:  J Virol       Date:  2012-05-23       Impact factor: 5.103

4.  Influence of IFNL3.rs12979860 and IFNL4.ss469415590 polymorphism on clearance of hepatitis C virus infection among Egyptians.

Authors:  Susanne Knapp; Zainab Zakaria; Mohamed Hashem; Hassan Zaghla; Salim I Khakoo; Imam Waked; Mark Thursz; Sayed F Abdelwahab
Journal:  Hepatol Int       Date:  2015-03-12       Impact factor: 6.047

Review 5.  Global elimination of hepatitis C virus infection: Progresses and the remaining challenges.

Authors:  Reza Taherkhani; Fatemeh Farshadpour
Journal:  World J Hepatol       Date:  2017-11-28
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.